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http:WHAT THIS PAPER ADDS
Factor Xa inhibitors and particularly those not requiring initial parenteral anticoagulation are more effective
than VKAs in preventing recurrent VTE in the form of deep vein thrombosis (DVT) during VTE treatment. NOAs
reduce major bleeding and fatal bleeding compared to VKAs, leading net clinical beneﬁt to favor NOAs. In
secondary prevention, NOAs reduce the all-cause mortality rate compared to placebo, while net clinical beneﬁt
and a small number needed to treat (NNT) both favor NOAs.Objectives: The aim was to perform a review of the efﬁcacy and safety of new oral anticoagulants (NOAs) in the
management of venous thromboembolism (VTE).
Methods: This was a systematic review and meta-analysis. On March 26, 2014, Medline, Embase, and the
Cochrane trial register were searched for randomized controlled trials (RCTs) comparing the NOAs dabigatran,
rivaroxaban, apixaban, and edoxaban with vitamin K antagonists (VKAs) in VTE treatment and secondary
prevention. Two investigators assessed the methodological quality of the RCTs. The main study outcomes
(efﬁcacy, safety and net clinical beneﬁt) were expressed as risk ratios (RR) with 95% conﬁdence interval (CI).
Results: Ten RCTs, mostly with low risk of bias, with nearly 38,000 patients, were identiﬁed. In six trials of treatment,
NOAswere equally effective as VKAs in preventing recurrent symptomatic VTE (RR 0.89, 95% CI 0.75e1.05), butmajor
bleeding occurred less often (1.08%vs. 1.73% forVKAs, RR0.63, 95%CI 0.51e0.77), leading net clinical beneﬁt to favor
NOAs (RR 0.79, 95% CI 0.70e0.90). Fatal bleeding occurred less often with NOAs (0.09% vs. 0.18% for VKAs), a
difference that approached statistical signiﬁcance (RR 0.51, 95% CI 0.26e1.01). In three secondary prevention trials,
NOAs reducedVTE recurrence rates to 1.32% (vs. 7.24%with placebo, RR 0.17, 95%CI 0.12e0.24) and fatal pulmonary
embolism (PE) (including unexplained deaths) to 0.1% (vs. 0.29% for placebo, RR 0.37, 95% CI 0.10e1.38) at the
expense of clinically relevant non-major bleeding (4.3% vs. 1.8% for placebo, RR 2.32, 95% CI 1.65e3.35), but not
major bleeding. All-cause mortality rate was reduced to 0.41% with NOAs (vs. 0.86% with placebo, RR 0.38, 95% CI
0.18e0.79). Net clinical beneﬁt favored NOAs (RR 0.21, 95% CI 0.15e0.29), and NNT was 18.
Conclusions: Compared to VKAs, NOAs are not only effective in treating VTE but also safer in terms of bleeding,
thereby conferring clinical beneﬁt. Their safety and efﬁcacy was conﬁrmed further in secondary prevention trials.
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For the last 60 years since warfarin was ﬁrst approved for
human use as an oral anticoagulant, vitamin K antagonistsTo access continuing medical education questions on this paper,
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Open access under CC BY-NC-ND license.(VKAs) have played a unique role in treating venous
thromboembolism (VTE) saving millions of lives. Although
more effective than ﬁxed low-dose subcutaneous heparin,
adjusted-dose warfarin is however associated with a higher
incidence of bleeding.1 Food and drug interactions are well-
known limitations of all VKAs, which can further reduce
their otherwise narrow therapeutic window, partially
responsible for post-thrombotic syndrome in association
with subtheraputic international normalized ratio (INR),2
and bleeding in association with coagulopathy. The above
facts dictate dose titration based on regular INR measure-
ments, which incur some costs, in addition to the logistics of
advising patients of the correct warfarin dose.
Figure 1. PRISMA ﬂow diagram showing the selection process of suitable randomized controlled trials for meta-analysis.
566 S.K. Kakkos et al.Recently, new oral anticoagulants (NOAs) have been
developed, which are not only as effective as warfarin in
treating VTE, but do not require adjustment of their dose
based on blood tests.3e7 These include factor Xa inhibitors
(rivaroxaban, apixaban, and edoxaban) and factor IIa
(thrombin) inhibitors (dabigatran), already completed phase
III testing against VKAs in VTE treatment and placebo in VTE
secondary prevention. However the original trials might
have been underpowered for certain efﬁcacy and safety
measures or had a non-inferiority design, which formed the
rationale of the present investigation. Therefore, the aim of
the present systematic review and meta-analysis was to
further study the effectiveness and safety of NOAs.
MATERIALS AND METHODS
Search method
On March 26, 2014, an up-to-date literature search of three
electronic databases was conducted (Medline, Embase, and
the Cochrane trial register) using the following keywords for
NOAs, rivaroxaban, apixaban, edoxaban, or dabigatran,
restricted to VTE. The aim was to identify randomizedcontrolled trials (RCTs) investigating the efﬁcacy and safety
of NOAs in the treatment and also secondary prevention (as
long-term treatment for non-provoked/idiopathic VTE is
called nowadays) of VTE (deep vein thrombosis [DVT] and/
or pulmonary embolism [PE]). This was followed by a
manual search of the reference list of the relevant articles
to identify additional studies. Studies published in lan-
guages other than English or in abstract form were not
considered. Unpublished data (e.g. from the manufacturers
and the authors of the included studies) were not sought,
but the full-text article of each RCT and its Supplementary
Appendix were both obtained and used. The study selection
process (PRISMA ﬂow-diagram) is shown in Fig. 1. For each
RCT included in the study, raw data (number of patients
who developed an end-point and total number of patients
in the intervention and control groups) were extracted by
two of the authors (SKK and GIK) and entered indepen-
dently into the meta-analysis software Review Manager
(RevMan, version 5.2. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2012); all entries
were compared and any disagreement was resolved by
discussion.
Table 1. Characteristics of the studies of NOAs in VTE treatment, including population, intervention, comparator and primary outcomes.
Study name Patient population Intervention Comparator Primary outcomes
RE-COVER8 VTE Dabigatrana Warfarin Recurrent symptomatic VTE and related deaths.
Bleeding events, acute coronary syndromes,
other adverse events, and results of liver function
tests.
RE-COVER II15 VTE Dabigatrana Warfarin Recurrent symptomatic VTE and related deaths.
RE-MEDY11 Post VTE treatment Dabigatran Warfarin Recurrent symptomatic VTE or death associated
with VTE. Clinically relevant bleeding.
RE-SONATE11 Post VTE treatment Dabigatran Placebo Recurrent symptomatic VTE or death associated
with VTE or unexplained death. Clinically relevant
bleeding.
EINSTEIN-DVT9 b DVT Rivaroxaban VKAs Recurrent symptomatic VTE (a composite of DVT,
nonfatal and fatal PE) or unexplained death.
Clinically relevant bleeding.
EINSTEIN-PE10 b PE  DVT Rivaroxaban VKAs Recurrent symptomatic VTE (a composite of DVT,
fatal and nonfatal PE) or unexplained death.
Clinically relevant bleeding.
EINSTEIN-EXT9 Post VTE treatment Rivaroxaban Placebo Recurrent symptomatic VTE (a composite of DVT,
nonfatal and fatal PE) or unexplained death.
Major bleeding.
AMPLIFY13 VTE Apixaban Warfarin Recurrent symptomatic VTE (a composite of DVT,
nonfatal and fatal PE) or unexplained death.
Major bleeding.
AMPLIFY-EXT12 Post VTE treatment Apixaban Placebo Recurrent symptomatic VTE (a composite of DVT,
fatal and nonfatal PE) or death from any cause.
Major bleeding.
HOKUSAI-VTE14 VTE Edoxabana Warfarin Recurrent symptomatic VTE (a composite of DVT,
nonfatal and fatal PE) or unexplained death.
Clinically relevant bleeding.
Note. Clinically relevant bleeding: A composite of major and clinically relevant non-major bleeding. DVT ¼ deep vein thrombosis;
NOA ¼ new oral anticoagulant; PE ¼ pulmonary embolism; VTE ¼ venous thromboembolism.
a Initial parenteral anticoagulation for a median of 7e9.6 days, mostly with low molecular weight heparin.
b Open-label design.
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The following information was retrieved from each RCT:
1. Efﬁcacy, related to recurrence of VTE, including fatal and
symptomatic PE and recurrent DVT.
2. Safety, including major, clinically relevant non-major and
any bleeding, and death due to bleeding, unexplained
death probably due to PE, and all-cause mortality.
3. Net clinical beneﬁt, deﬁned as the composite outcome
of VTE recurrence and major bleeding.Methodological assessment
The risk of bias assessment tool RevMan was used to assess
the methodological quality of the included studies. Two of
the authors (SKK and GIK) performed an independent
assessment; any disagreement was resolved by discussion.
Data synthesis
RCTs on VTE treatment were analyzed separately from those
on secondary prevention of VTE. As stated above, raw data
were entered into RevMan, which performed the meta-
analyses (ManteleHaenszel method), calculated the riskratio (RR) and its 95% conﬁdence interval (CI), produced
forest plots, and provided inconsistency (I2) statistics to
evaluate the heterogeneity of the included studies. A non-
signiﬁcant p value for the Cochrane Q statistic indicates
that the included studies are homogeneous. An I2 value of 0%
indicates no heterogeneity, while larger values are consistent
with increasing heterogeneity. An I2 over 50% is indicative of
substantial heterogeneity. In case of statistically signiﬁcant
heterogeneity (p< .05) a random effects model was chosen,
instead of the ﬁxed effect model. Sensitivity analysis was
performed in order to address possible heterogeneity intro-
duced by pooling studies on factor Xa inhibitors (rivaroxaban,
apixaban, and edoxaban) and factor IIa (thrombin) inhibitors
(dabigatran), on NOAs requiring initial parenteral anticoag-
ulant treatment (i.e. dabigatran and edoxaban), and NOAs
not requiring initial parenteral anticoagulant treatment (i.e.
rivaroxaban and apixaban). Additionally, the analyses were
repeated by excluding studies having a high risk of bias.
GraphPad QuickCalcs (http://www.graphpad.com, GraphPad
Software Inc., San Diego, CA, USA) was used to calculate the
number needed to treat (NNT), in order to prevent one
negative outcome (the reciprocal of the difference between
the event rate in the two groups, known also as absolute risk
reduction, multiplied by 100).
Figure 2. Risk of bias graph demonstrating a mostly uniform low risk of bias.
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Some 2,844 potential trials (after removing the duplicates)
were identiﬁed on the literature search (PRISMA ﬂow dia-
gram, Fig. 1). After excluding 2,827 of them based on their
title and abstract, and an additional nine because they were
abstracts (n ¼ 4), irrelevant (n ¼ 3), or dose-ranging studies
(n ¼ 2) after reading their full text, eight publications
reporting 10 RCTs remained.8e15
The design of the included studies is shown in Table 1.
Eight were double-blind trials and the remaining two had an
open-label design. Six RCTs investigated VTE treatment
(NOA compared with heparin/VKA) and the remaining four
were on secondary prevention of VTE (NOA compared with
placebo in three trials and warfarin in the remaining one,
the latter not being amenable to meta-analysis). Enoxaparin
and warfarin were the anticoagulants mostly frequently
used, followed by unfractionated heparin and acenocou-
marol, respectively. For dabigatran and edoxaban, initial
parenteral anticoagulant treatment, most often with a low-
molecular-weight heparin, was used in trials of treat-
ment.8,14,15 Recurrent symptomatic VTE, deﬁned as the
composite of DVT, non-fatal PE, and fatal PE, was the most
commonly used efﬁcacy outcome. In most studies, unex-
plained death that could not be attributed to a documented
cause, or where pulmonary embolism could not be ruled
out, was classiﬁed as fatal PE and considered to be part of
the primary efﬁcacy outcome. Clinically relevant bleeding, a
composite of major and clinically relevant non-major
bleeding, was the mostly frequently used safety outcome,
while major bleeding was used in others. All studies used
the International Society on Thrombosis and Haemostasis
criteria for major bleeding.16 All studies on factor Xa in-
hibitors used the van Gogh investigators criteria for clini-
cally relevant non-major minor bleeding,17 while those on
factor IIa inhibitors used uniform study-speciﬁc criteria.
RCTs of treatment included approximately 27,000 pa-
tients (27,023 were included in the efﬁcacy analysis and
26,958 were included in the safety analysis). RCTs of sec-
ondary prevention included 10,744 patients, but after
excluding the RE-MEDY trial because it was not amenable to
meta-analysis, 7,877 patients were left in the study. Risk of
bias was mostly low, as shown in Fig. 2.Treatment
Compared to standard treatment with VKAs, NOAs were
equally effective in preventing recurrent symptomatic VTE
(RR 0.89, 95% CI 0.75e1.05, p ¼ .16, Fig. 3a). Similar
ﬁndings were obtained for DVT (RR 0.85, 95% CI 0.69e1.06,
p ¼ .15, Fig. 3b), and PE (fatal, Fig. 3c, or non-fatal, Fig. 3d).
Pooled recurrent DVT rates were 1.3% for the use of
traditional treatment and 1.1% for the use of NOAs. Het-
erogeneity was negligible and not statistically signiﬁcant
throughout the comparisons with I2 being 0 in all but one of
them.
Bleeding in the form of major bleeding or clinically
relevant non-major bleeding was statistically signiﬁcantly
reduced with NOAs compared with traditional treatment.
Major bleeding rates fell from 1.73% with the use of
traditional treatment to 1.08% with the use of NOAs (RR
0.63, 95% CI 0.51e0.77, p < .00001, Fig. 4a). NNT was 155,
95% CI 108e274.5. For clinically relevant non-major
bleeding, these rates were 8.5% and 6.6%, respectively
(RR 0.74, 95% CI 0.59e0.93, p ¼ .01, Fig. 4b). NNT was 52,
95% CI 39.1e77.1. However, a signiﬁcant degree of statis-
tically signiﬁcant heterogeneity was observed for both
forms of bleeding.
There was no difference in all-cause mortality between
the two study groups (Fig 4c). However fatal bleeding
reached statistical signiﬁcance in favor of NOAs (0.18% vs.
0.09% for NOAs, RR 0.51, 95% CI 0.26e1.01, p ¼ .05, Fig
4d). No heterogeneity was evident in these analyses.
Net clinical beneﬁt was in favor of NOAs (RR 0.79, 95% CI
0.70e0.90, p ¼ .0003, Fig. 4e) with a small degree of non-
signiﬁcant heterogeneity. NNT was 122 (95% CI 79.1e
262.1).
The results of sensitivity analysis are shown in Table 2.
Factor Xa inhibitors and NOAs not requiring initial paren-
teral anticoagulation were associated with a reduced inci-
dence of recurrent DVT compared to VKAs, with the
difference being statistically signiﬁcant (RR 0.77, 95% CI
0.60e0.99, p ¼ .04 and RR 0.67, 95% CI 0.47e0.94, p ¼ .02,
respectively). A similar pattern of ﬁndings was observed for
major bleeding and net clinical beneﬁt, with the latter being
greatest for NOAs not requiring initial parenteral anti-
coagulation (rivaroxaban and apixaban). Fatal bleeding
ab
c
d
Figure 3. Efﬁcacy of new oral anticoagulants (NOAs) in the treatment of venous thromboembolism (VTE). NOAs were more effective than
vitamin K antagonists (VKAs) in preventing recurrent symptomatic VTE (Fig. 3a). This difference was exclusively driven by an also non-
signiﬁcant reduction of deep vein thrombosis (Fig. 3b). Such a trend was not observed for fatal pulmonary embolism (PE) (Fig. 3c) or
non-fatal PE (Fig. 3d).
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hibitors, but only with NOAs requiring initial parenteral
anticoagulation (dabigatran and edoxaban) was the differ-
ence signiﬁcant. Finally, the exclusion of the two high-risk of
bias open-label EINSTEIN-DVT and EINSTEIN-PE studies
further strengthened the association of NOAs with a
reduced risk of fatal bleeding (RR 0.36, 95% CI 0.13e0.94,
p ¼ .04).Secondary prevention
One RCT (RE-MEDY) compared dabigatran with warfarin;
recurrent VTE occurred in 26 of 1,430 patients in the
dabigatran group (1.8%) and 18 of 1,426 patients in the
warfarin group (1.3%) (p ¼ .01 for non-inferiority). Major or
clinically relevant bleeding was less frequent with dabiga-
tran (hazard ratio, 0.54; 95% CI 0.41e0.71), but major
bleeding occurred equally frequently.After excluding the above single RCT comparing dabiga-
tran with warfarin, three RCTs comparing NOAs with pla-
cebo (Table 1) were eligible for meta-analysis.
NOAs reduced VTE recurrence rate from 7.24% with
placebo to 1.32%, an absolute reduction rate of 5.92% (RR
0.17, 95% CI 0.12e0.24, p < .00001, Fig. 5a). The same
ﬁndings were observed for both DVT and PE (Fig. 5b,c).
Fatal PE (including unexplained deaths) was reduced from
0.29% to 0.1%, but the difference did not reach statistical
signiﬁcance (RR 0.37, 95% CI 0.10e1.38, p ¼ .14, Fig. 5d).
There was only one case of documented fatal PE in these
three studies, which occurred in the control group of the
EINSTEIN Extension study. Heterogeneity was not present,
with the exception of PE, where it was found to be mod-
erate but not statistically signiﬁcant.
Clinically relevant non-major bleeding occurred more
often with NOA use than placebo, with pooled rates of 4.3%
versus 1.8% (RR 2.32, 95% CI 1.65e3.35, p < .00001,
ab
c
d
e
Figure 4. Safety and net clinical beneﬁt of new oral anticoagulants (NOAs) in the treatment of venous thromboembolism (VTE). Major
bleeding rates fell from 1.73% with vitamin K antagonists (VKAs) to 1.08% with NOAs, (Fig. 4a). For clinically relevant non-major bleeding,
these rates were 8.5% and 6.6%, respectively (Fig. 4b). All-cause mortality rates were similar for NOAs and VKAs (Fig. 4c) in VTE treatment;
however fatal bleeding rates approached statistical signiﬁcance in favor of NOAs (Fig. 4d). Net clinical beneﬁt was in favor of NOAs
(Fig. 4e).
570 S.K. Kakkos et al.Fig. 6a); similar ﬁndings were seen for any bleeding
(Fig. 6b). However, major bleeding occurred with equal
frequency in the two groups (p ¼ .49, Fig. 6c) and was
never fatal. A substantial amount of heterogeneity was
present in all analyses for bleeding; however, it was statis-
tically signiﬁcant only for any bleeding.All-cause mortality rate was reduced from 0.86% with
placebo to 0.41% with NOAs (RR 0.38, 95% CI 0.18e0.79,
p ¼ .009, Fig. 6d) and NNT was 220. Net clinical beneﬁt was
in favor of NOAs (RR 0.21, 95% CI 0.15e0.29, p < .00001,
Fig. 6e). NNT was 18 (95% CI 14.3e21.8). No heterogeneity
was evident for these two outcomes.
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(rivaroxaban and apixaban, both not requiring initial anti-
coagulation with heparin), altered the results only slightly,
with clinically relevant and any bleeding becoming non-
signiﬁcant.DISCUSSION
In the present meta-analysis, factor Xa inhibitors and
particularly those not requiring initial anticoagulation were
found to be superior to VKAs in treating VTE associated
with a reduced risk of recurrent DVT. NOAs were also safer
than VKAs in terms of bleeding. Additionally, the three
secondary prevention trials included in the present review
further conﬁrmed the value of NOAs, by demonstrating a
reduced risk of the efﬁcacy outcomes when compared
with placebo at the expense of increased clinically relevant
non-major bleeding rates. The large number of patients,
approximately 35,000, included in this meta-analysis of the
nine RCTs allowed conclusions to be reached for relatively
rare events in these trials including mortality rates.
In the present meta-analysis, NOAs were more effective
than VKAs in preventing recurrent VTE, unlike what has
been previously reported by an earlier meta-analysis;18
however, statistical signiﬁcance was restricted to DVT in
studies comparing factor Xa inhibitors, particularly those
not requiring initial parenteral anticoagulation. On the
other hand, fatal and non-fatal PE occurred equally
frequently with NOAs and VKAs, indicating a different
mechanism of action. PE is caused by emboli breaking off a
DVT, which can be minimized by proper anticoagulation
and this is probably true for the thrombus tail, but, as
suspected, not for residual “random” embolization unaf-
fected by anticoagulation. Alternatively, in patients on
VKAs only, DVT recurrence might be more sensitive to
subtherapeutic INR than PE recurrence. The results of the
included trials were almost completely homogeneous with
a negligible I2 for DVT, and fatal and non-fatal PE, a fact
that strengthens the observation. A constant trend
throughout the sensitivity analysis (Table 2) towards a
higher rate of fatal PE is seen, but the small number of
fatal PEs (21 in total) renders these comparisons under-
powered; this is not the case for non-fatal, PE where the
negligible difference between the two groups makes any
further update unlikely to show any beneﬁt. Of note, a
similar improved efﬁcacy of the NOAs compared to
enoxaparin has been shown in thromboprophylaxis trials
after total hip or knee arthroplasty.19
Major and clinically relevant major bleeding rates were
both signiﬁcantly reduced with NOAs compared to VKAs,
unlike what has been generally reported by a similar meta-
analysis.18 There was a high degree of heterogeneity,
indicative of differential pharmacological properties of the
various NOAs or different levels of within-target INR con-
trol, shown to modulate relative reductions in major
bleeding.20 In the present meta-analysis, fatal bleeding
rates approached statistical signiﬁcance in favor of NOAs.
However, the best results were shown for NOAs requiring
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Figure 5. Efﬁcacy of new oral anticoagulants (NOAs) in venous thromboembolism (VTE) secondary prevention trials. NOAs reduced VTE
recurrence rates from 7.24% with placebo to 1.32% (Fig. 5a). The same ﬁndings were observed for both deep vein thrombosis and
pulmonary embolism (Fig. 5b and c, respectively). Fatal pulmonary embolism (including unexplained deaths) was reduced from 0.29% to
0.1% (Fig. 5d).
572 S.K. Kakkos et al.initial parenteral anticoagulation (RR 0.28, Table 2), which
were shown to be less effective in preventing recurrent VTE
and DVT. Similar ﬁndings on fatal bleeding have been shown
by several studies: a recently published similar meta-anal-
ysis,21 a meta-analysis on rivaroxaban that included trials in
patients with VTE and atrial ﬁbrillation,22 and another meta-
analysis of trials in patients with atrial ﬁbrillation and pre-
vious stroke or transient ischemic attacks, where NOAs
were associated with a signiﬁcant reduction of major
bleeding compared to warfarin (OR 0.86, 95% CI 075e0.99;
NNT 125),23 mainly driven by the signiﬁcant reduction of
intracranial bleeding (OR 0.44, 95% CI, 0.32e0.62) and
despite a non-signiﬁcant increase in gastrointestinal
bleeding. These ﬁndings have been largely reproduced by
others.24
Unlike studies of patients with atrial ﬁbrillation,20 all-
cause mortality in the VTE trials included herein was
similar and very low (around 2.4%) for both NOAs and VKAs,
probably because of the younger patient population and
the rare occurrence of fatal PE of around 0.8%. Not sur-
prisingly, net clinical beneﬁt (the combination of VTE
recurrence and major bleeding) was better for NOAs than
VKAs (RR 0.79), a difference that was not only statisticallysigniﬁcant but also clinically important. This difference
clearly supports the recently reported superior cost-
effectiveness of rivaroxaban in treating VTE.25,26 However,
statistical signiﬁcance was shown only for factor Xa in-
hibitors and those not requiring initial parenteral
anticoagulation.
In the secondary prevention trials, as expected for potent
anticoagulants, NOAs signiﬁcantly reduced VTE recurrence
rates to 1.32% compared to 7.24% with placebo; the latter
VTE rates were observed at 12 months’ follow-up, and are
highly comparable with VTE rates in patients with idiopathic
VTE discontinuing anticoagulation.27e29 The all-cause mor-
tality rate was reduced with NOAs, which indicates the
strong effect of VTE on fatalities that were otherwise
thought not to be related to VTE and the clinical necessity
for long-term secondary prevention of VTE when indicated.
This gain was made at the expense of clinically relevant
non-major bleeding (4.3% vs. 1.8% for placebo), but not
major bleeding. Finally, net clinical beneﬁt favored NOAs;
the small RR and NNT (0.21 and 18, respectively) are both
indicative of their safety and efﬁcacy proﬁle.
Our meta-analysis has some limitations. Sensitivity anal-
ysis shown in Table 2 is a form of multiple testing, which
ab
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Figure 6. Safety and net clinical beneﬁt of new oral anticoagulants (NOAs) in venous thromboembolism secondary prevention trials.
Clinically relevant non-major bleeding occurred more often with NOA use compared to placebo, pooled rates of 4.3% versus 1.8% (Fig. 6a);
similar ﬁndings were seen for any bleeding (Fig. 6b). Major bleeding occurred equally frequently with NOAs and placebo (Fig. 6c). All-cause
mortality rates were reduced from 0.86% with placebo to 0.41% with NOAs (Fig. 6d). Net clinical beneﬁt was in favor of NOAs (Fig. 6e).
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be viewed with caution. Additionally, sensitivity analyses to
explore the high degree of heterogeneity seen in most
bleeding types across the entire meta-analysis (treatment
and secondary prevention), probably related to different
pharmacological properties, pharmacodynamics, anti-
coagulation intensity, and dosing schedule of the various
agents, could not be performed for each NOA separately,
because of the small number of studies involving different
agents. However, a meta-analysis of the two dabigatran (RE-
COVER) studies has been recently published.15 Additionally,
data were not collected for intracranial hemorrhage, re-
ported to occur less often with NOAs,23,30 and gastroin-
testinal bleeding, reported to occur more often with
NOAs,31 although there is debate on the latter issue.30
Finally, meta-analysis of acute coronary events, reported
to occur more often with dabigatran,32 was not performed.On the other hand, the current meta-analysis has included
all phase III trials that have been performed to date on the
four NOAs; therefore, these results are unlikely to change in
the near future.
Cost-effectiveness studies for rivaroxaban used in the VTE
setting have recently been published.25,26 Future work
should explore the cost-effectiveness of all NOAs and
compare them. Additionally, subgroup analysis for the index
event (DVT only and PE, with or without DVT, not performed
here) should be performed. In this meta-analysis rivarox-
aban was better than standard treatment in patients pre-
senting with DVT (EINSTEIN-DVT trial) but not PE (EINSTEIN-
PE trial) (Fig. 3a). This trend however was not seen for the
other three NOAs.8,13,14 Regarding hemorrhage, the initial
fear that NOAs would be associated with excessive bleeding
compared to standard anticoagulation treatment is not
supported by the present study. Further clinical experience
574 S.K. Kakkos et al.with the recently developed factor Xa inhibitor antidote,
andexanet alfa (PRT4445, Portola Pharmaceuticals, Inc),33 is
expected to resolve concerns over the reversal of NOAs
when needed. Post-thrombotic syndrome rates, known to
be higher in patients on warfarin with subtherapeutic INR,
and lower when the low-molecular-weight heparin tinza-
parin is used,34 might be better with NOAs than VKAs; the
lower recurrence rate with NOAs during initial treatment,
especially DVT, but also during extended treatment sup-
ports this hypothesis, which should be explored further.
In conclusion, NOAs are not only effective in treating VTE,
but also safer in terms of bleeding, than VKAs, conferring
clinical beneﬁt. The safety and efﬁcacy proﬁle of NOAs was
conﬁrmed further in secondary prevention trials.FUNDING
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